Additional Preclinical Combination Data to be Presented This Year
Clinical Combination Studies to Begin in 2017
VANCOUVER, Canada and DOYLESTOWN, PA, USA I April 22, 2016 I Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentations this week by Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, on results of several preclinical HBV drug combination studies at the 29th International Conference on Antiviral Research held April 17-21, and Cambridge Healthtech Institute’s 11th Annual Drug Discovery Chemistry conference held April 19-22, 2016, both in San Diego.
“We are excited to present this intriguing data from our preclinical drug combination studies. These data show additive or synergistic activity in in vitro and in vivo studies that evaluate different HBV disease markers such as cccDNA synthesis and expression, HBV rcDNA synthesis, HBsAg production and serum HBV DNA. We believe that combination therapy will enable an HBV cure with a finite treatment duration, and we have built a diverse pipeline of HBV product candidates at Arbutus to support this strategy,” said Dr. Sofia. “Our thorough preclinical evaluation of combinations of HBV candidates with different direct acting anti-viral mechanisms of action will inform our proprietary clinical combination studies, which will begin in 2017.”
These initial preclinical combination studies have established the following:
- Our drug candidates ARB-1467, AB-423, and AB-199 are potent and selective inhibitors of their respective targets.
- These drug candidates can be used in combination with the ‘nuc’ standard of care without any antagonism of drug activity.
- These drug candidates when used in combination with the ‘nuc’ standard of care demonstrate at least additive and in some cases synergistic activity.
- That our first proprietary drug combination, RNAi plus capsid formation inhibitor, also demonstrates additive activity.
- These results support Arbutus’ combination strategy.
Summary of the Studies Presented:
| Combination |
Study(ies) |
| AB-423 (core protein/capsid inhibitor) with entecavir (EVT) |
In vitro and in vivo |
| AB-423 (core protein/capsid inhibitor) with ARB-1467 (RNAi) |
In vitro and in vivo |
| ARB-1467 (RNAi) with EVT |
In vitro |
| ARB-199 (cccDNA formation inhibitor) with EVT |
In vitro |
| ARB-199 (cccDNA formation inhibitor) with lamivudine |
In vitro |
| |
|
The presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
SOURCE: Arbutus Biopharma
Post Views: 111
Additional Preclinical Combination Data to be Presented This Year
Clinical Combination Studies to Begin in 2017
VANCOUVER, Canada and DOYLESTOWN, PA, USA I April 22, 2016 I Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentations this week by Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, on results of several preclinical HBV drug combination studies at the 29th International Conference on Antiviral Research held April 17-21, and Cambridge Healthtech Institute’s 11th Annual Drug Discovery Chemistry conference held April 19-22, 2016, both in San Diego.
“We are excited to present this intriguing data from our preclinical drug combination studies. These data show additive or synergistic activity in in vitro and in vivo studies that evaluate different HBV disease markers such as cccDNA synthesis and expression, HBV rcDNA synthesis, HBsAg production and serum HBV DNA. We believe that combination therapy will enable an HBV cure with a finite treatment duration, and we have built a diverse pipeline of HBV product candidates at Arbutus to support this strategy,” said Dr. Sofia. “Our thorough preclinical evaluation of combinations of HBV candidates with different direct acting anti-viral mechanisms of action will inform our proprietary clinical combination studies, which will begin in 2017.”
These initial preclinical combination studies have established the following:
- Our drug candidates ARB-1467, AB-423, and AB-199 are potent and selective inhibitors of their respective targets.
- These drug candidates can be used in combination with the ‘nuc’ standard of care without any antagonism of drug activity.
- These drug candidates when used in combination with the ‘nuc’ standard of care demonstrate at least additive and in some cases synergistic activity.
- That our first proprietary drug combination, RNAi plus capsid formation inhibitor, also demonstrates additive activity.
- These results support Arbutus’ combination strategy.
Summary of the Studies Presented:
| Combination |
Study(ies) |
| AB-423 (core protein/capsid inhibitor) with entecavir (EVT) |
In vitro and in vivo |
| AB-423 (core protein/capsid inhibitor) with ARB-1467 (RNAi) |
In vitro and in vivo |
| ARB-1467 (RNAi) with EVT |
In vitro |
| ARB-199 (cccDNA formation inhibitor) with EVT |
In vitro |
| ARB-199 (cccDNA formation inhibitor) with lamivudine |
In vitro |
| |
|
The presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
SOURCE: Arbutus Biopharma
Post Views: 111
